Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Seres Therapeutics Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Seres Therapeutics (NASDAQ:MCRB) reported Q1 sales of $1.49 million. Earnings fell to a loss of $56.62 million, resulting in a 13.25% decrease from last quarter. In Q4, Seres Therapeutics brought in $7.22 million in sales but lost $50.00 million in earnings.

What Is ROCE?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.